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Table
Pediatric HSCT Blood Pressure Data (Day +0 to Day +5)
Number of pediatric HSCT patients 6
Patients age 6 month-14 years
Type of HSCT allogeneic matched
unrelated donor
Number of myeloablative HSCT 2 of 6
Number of reduced intensity HSCT 4 of 6
Number of patients with initial BP
parameters ordered that were above
>95% for age and height or above
age speciﬁc percentiles for birth to
12 months of age
3/6
Total number of blood pressure (BP) data
points (Day +0 to Day +5)
458
Median number of elevated systolic BPs
documented before a BP medication
was ﬁrst ordered
30
Median number of diastolic BPs
documented before a BP medication
as ﬁrst ordered
16
Median Time in hours to Initial
antihypertensive medication delivery
after elevated BPs were documented
64.5
Most frequently used antihypertensive
medications
Hydralazine (as needed)
Nicardipine (as needed)
Amlodipine
(1-2 times daily)
Enalaprilat (every
8 hours)
Abstracts / Biol Blood Marrow Transplant 19 (2013) S355eS369S358practitioners (NP) screen all donors and determine eligibility
based on a history and physical, review of a Health History
Questionnaire (HHQ), and various diagnostic tests. The
Foundation for the Accreditation of Cellular Therapy (FACT),
set standards of operation to promote quality medical and
laboratory practice in hematopoietic transplantation and
other cellular therapy products. Adherence to the FACT
standards helps to ensure donor eligibility thereby reducing
the risks of transmissible diseases. The HHQ guides the NP in
determining donor eligibility. A retrospective chart review of
46 medical records from January 2011 through December
2011 revealed the rate of accuracy of 60% in determining
donor eligibility based upon FACT criteria. All donors (46)
were deemed as eligible; however, only 28 met FACT criteria
for eligibility. Eighteen patients were ineligible; yet they
were medically acceptable to donate. Reasons for ineligibility
included: a missing or incomplete HHQ, a tattoo within
a year, donor lived in Europe. NPs were re-educated
regarding FACT criteria and how to use the HHQ when
determining eligibility. A tool provided a guideline for the
NPs highlighting special considerations for donors that
would make them potentially ineligible. Following these
interventions, the rate of accuracy improved to 84%. From
June 2012 to September 2012, 19 medical records were
reviewed 16 met FACT criteria for eligibility. By re-educating
NPs about FACT guidelines, NPs were able to utilize the HHQ
as a crucial step in their assessment process and improve the
rate of accuracy in determining donor eligibility thus
improving donor screening.502
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Hypertension (HTN) is a known complication of pediatric
hematopoietic stem cell transplant (HSCT). Historically, the
risks for developing HTN depend on a variety of factors which
may includeuseof calcineurin inhibitors, thepresenceof graft
versus host disease requiring steroid therapy, total body
irradiation, and standardized chemotherapy delivered during
HSCT. Uncontrolled HTN in pediatric HSCT patients may lead
to signiﬁcant life threatening complications that often affect
long term cardiac and renal outcomes. Managing pediatric
HSCT associated HTN is often a challenge due to the range of
patients ages, heights and weights which determine normal
and target blood pressure. Using a multidisciplinary
approach, we collected pilot data from 6 pediatric patients
whohad received allogeneicHSCTs fromday +0 to day +5. The
focus was to look at their hypertension management within
the ﬁrst days following their stem cell infusions. The data
consisted of blood pressure parameters ordered, documented
blood pressures, the response time for reporting HTN and the
antihypertensive medications given to patients during that
period. The table below lists the data obtained. We found 3
areas to focus improvements on. One was to educate staff on
the use of the individualized blood pressure parameters(<95% for age and height, Pediatrics 2004; 114; 555-576,
infants birth -12 months parameters, Pediatric Nephrology
(2012) 27:17-32) in the initial order set. A second area was to
educate staff on the process of taking blood pressures
according to the published guidelines followed by our
nephrology and HTN clinics. A third improvement opportu-
nitywas to decrease the time to initiation of antihypertensive
therapy. Overall the goal is to protect the pediatric patients
throughout HSCT. This is a process that the multidisciplinary
HSCT team continues to focus and improve upon, thus
impacting the outcomes for our pediatric BMT population.
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Background: At an NCI-designated Cancer Institution with
76 inpatient stem cell transplant (SCT) patients and a bur-
geoning staff, addressing continuity of care and patient
satisfaction is an on-going opportunity for growth and
innovation. Press-Ganey patient satisfaction data revealed
that patients wanted more consistency in care, improved
communication, and increased involvement in their treat-
ment plan. In response, a nurse-driven, patient-centered
initiative examined the efﬁcacy of creating individualized
care plans, customized to each patient's unique needs, in
collaboration with the patient and caregivers.
Purpose: To increase consistency of care, improve commu-
nication among nurses and patients, and raise patient satis-
faction, a nurse-developed and driven Individualized Care
Planning Process (ICPP) was developed.
Intervention: The ICPP engages nurse volunteers to be
responsible for thedevelopmentand trackingof individualized
